Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$172.78 USD

172.78
7,916,712

-1.04 (-0.60%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $173.01 +0.23 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DGRW

Mark Vickery headshot

Markets Stay Positive on Perceived Fed Slowing

by Mark Vickery

We're either letting the stern part of the narrative get past us or we're breathing some life into oversold indices. Perhaps a little of both.

Zacks Equity Research

Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance

by Zacks Equity Research

Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.

Andrew Rocco headshot

Market on Tipping Point of New Bull Trend: These 5 Charts Illustrate Why

by Andrew Rocco

You never really know when a new bull trend has arrived for sure. However, by looking at different sides of the market you can begin to put the pieces of the puzzle together.

Zacks Equity Research

Discover Financial, Kimberly Clark, Johnson & Johnson and Synchrony Financial are part of Zacks Earnings Preview

by Zacks Equity Research

Discover Financial, Kimberly Clark, Johnson & Johnson and Synchrony Financial are highlights of Zacks Earnings Preview article.

Sheraz Mian headshot

Making Sense of the Early Q4 Results: Is An Earnings Cliff Coming?

by Sheraz Mian

By the end of this week, we will have seen quarterly results from about 28% of all S&P 500 members and will have a very good sense of whether the earnings-cliff narrative has started unfolding or been further pushed out.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds

by Kinjel Shah

FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints

Zacks Equity Research

J&J (JNJ) to Begin Q4 Earnings Season for Pharma Sector

by Zacks Equity Research

Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.

Zacks Equity Research

Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VYM

Zacks Equity Research

J&J (JNJ) Discontinues HIV Vaccine Phase III Mosaico Study

by Zacks Equity Research

J&J (JNJ) discontinues phase III study on its investigational HIV vaccine regimen, which shows that the candidate lacks efficacy in preventing HIV.

Zacks Equity Research

Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VONV

Zacks Equity Research

Johnson & Johnson (JNJ) Stock Moves -1.51%: What You Should Know

by Zacks Equity Research

In the latest trading session, Johnson & Johnson (JNJ) closed at $169.76, marking a -1.51% move from the previous day.

Zacks Equity Research

Should Vanguard S&P 500 Value ETF (VOOV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VOOV

Zacks Equity Research

Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DGRO

Zacks Equity Research

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance

by Zacks Equity Research

Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.

Tracey Ryniec headshot

How to Use Zacks Earnings Surprise Charts

by Tracey Ryniec

If you're trading on the earnings report, you will want to check out these charts.

Zacks Equity Research

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Zacks Equity Research

Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MGV

Zacks Equity Research

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Zacks Equity Research

Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Johnson & Johnson (JNJ) closed at $175.16, marking a -0.24% move from the previous day.

Zacks Equity Research

Emergent (EBS) to Start Restructuring Plan, Lays Off 5% Workforce

by Zacks Equity Research

Once this restructuring activity is completed, Emergent BioSolutions (EBS) expects to result in annualized savings of over $60 million. It also slightly raised its total revenue guidance for 2022.

Zacks Equity Research

Should Invesco S&P 500 Low Volatility ETF (SPLV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPLV

Zacks Equity Research

FATE To End Janssen Deal and Prioritize Pipeline Development

by Zacks Equity Research

FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.